Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_assertion type Assertion NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_head.
- NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_assertion description "[To ensure cancer-specific targeting, efficient delivery, and efficacy, we developed an ovarian cancer-specific construct (Survivin-VISA-hEndoyCD) composed of the cancer specific promoter survivin in a transgene amplification vector (VISA; VP16-GAL4-WPRE integrated systemic amplifier) to express a secreted human endostatin-yeast cytosine deaminase fusion protein (hEndoyCD) for advanced ovarian cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_provenance.
- NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_assertion evidence source_evidence_literature NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_provenance.
- NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_assertion SIO_000772 22562248 NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_provenance.
- NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_assertion wasDerivedFrom befree-20140225 NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_provenance.
- NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_assertion wasGeneratedBy ECO_0000203 NP838252.RAa7Vdg-4hi7cfiKO5j0wp_4aP4mVY0-I_IcPEBPZlxSU130_provenance.